Development of monoclonal antibodies to prevent and treat infections from Flaviviruses

Description

Details Status Upcoming Reference HORIZON-HLTH-2027-01-DISEASE-06 Publication date 8 October 2026 in Funding and Tenders Portal Opening date 29 October 2026 Deadline model Single-stage Deadline date 17 February 2027, 17:00 (CET) Funding programme Horizon Europe – the Framework Programme for Research and Innovation (2021/2027) Programme Sector Health Programme Horizon Europe Horizon Europe Cluster 1: Health Tags EU financing Health preparedness Medical research Pharmaceutical industry Scientific research Description Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. Applicants should explicitly state in their proposal which of the following Flaviviruses is targeted and the proposed work should address only this specific Flavivirus. The proposed work should aim to advance the development of existing prophylactic and therapeutic monoclonal antibody candidates targeting exclusively one of the following Flaviviriuses: Dengue Virus Tick-borne Encephalitis Virus Japanese Encephalitis Virus West Nile Fever Virus Yellow Fever Virus Zika Virus Read more and apply on the Funding and Tenders Portal .

Sectors

Source

Source: hadea.ec.europa.eu